INFINITY PHARMA
ActiveSummary
INFINITY PHARMA has been active since 1976 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €16.4m and a net result of -€231,419. The figures fluctuate too strongly year-on-year for a reliable trend projection. Its solvency ranks better than 91% of 6,139 sector peers (NACE 46, financial year 2025). The computed 12-month bankruptcy probability is 0.3% (very low).
Financials · financial year 2025, full format
In the rankings
#7 company by equity in Nazareth-De Pinte, Wholesale and retail trade sector#8 company by total assets in Nazareth-De Pinte, Wholesale and retail trade sector
Turnover
€10.7m▲ 0.6%
2024 · €10.7m
EBIT margin
-0.7%▲ 4.3pp
2024 · -5.0%
Net result
-€231,419▲ 71.9%
2024 · -€822,517
Working capital
€1.1m▲ 425%
2024 · €200,859
Trend over the years
2021 to 2025, 5 financial years 2018 to 2025, 8 financial years
The operating result stays negative: a loss of €72,613 in 2025 against €531,006 in 2024; the loss shrinks.
What the company sold each financial year and what was left of it. A loss stands below the zero line.
Turnover€10.7m
2025
Operating result-€0.07m
2025
Net result-€0.2m
2025
What the company owns (total assets), how much of it is its own (equity) and how much it owes.
Total assets€18.8m
2025
Equity€16.4m
2025
Debt€2.4m
2025
Short-term assets minus short-term debts. Above zero the company can pay its bills in the short term.
Working capital€1.1m
2025
How much of each euro of turnover is left from operations (EBIT margin) and what the assets earn (return on assets).
EBIT margin-0.7%
2025
Return on assets (ROA)-1.2%
2025
The share of the company financed with its own means. The higher it is, the better it absorbs a shock.
Solvency87.2%
2025
Short-term assets per euro of short-term debt. Above 1 the short-term debts are covered.
Current ratio1.44
2025
Average staff in full-time equivalents (FTE).
Staff (FTE)13.6
2025
Use the arrow keys on the chart for the figures per year.
Sector: the middle half of NACE 46, Wholesale trade: a quarter of companies sit below it, a quarter above. Each year compared with accounts in the same format, and only where there are at least 30. Dashed line: the median. Available for Net result, Equity, Total assets, Working capital, Solvency, Current ratio, Return on assets (ROA), Staff (FTE).
Every figure with its change against the financial year before
favourable
unfavourable
Line20182019202020212022202320242025
Turnover€11.1m-€10.6m▼ 4.1%€15.7m▲ 47.7%€10.2m▼ 34.7%€7.2m▼ 29.8%€11.4m▲ 58.3%€10.7m▼ 6.2%€10.7m▲ 0.6%
Operating result€1.8m-€1.8m▼ 2.0%€2.2m▲ 21.8%-€0.5m-€0.05m▲ 88.0%-€0.3m▼ 427%-€0.5m▼ 85.7%-€0.07m▲ 86.3%
Net result€0.4m-€13.3m▲ 38×€28.4mabove the sector's middle half▲ 113%-€6.4mbelow the sector's middle half-€0.5mbelow the sector's middle half▲ 92.2%-€7.4mbelow the sector's middle half▼ 1,364%-€0.8mbelow the sector's middle half▲ 88.8%-€0.2mbelow the sector's middle half▲ 71.9%
EBIT margin16.7%-17.0%▲ 0.4pp14.0%▼ 3.0pp-4.4%▼ 18.4pp-0.8%▲ 3.6pp-2.5%▼ 1.8pp-5.0%▼ 2.5pp-0.7%▲ 4.3pp
Equity€3.0m-€9.4m▲ 209%€37.7mabove the sector's middle half▲ 303%€31.3mabove the sector's middle half▼ 17.0%€5.8mabove the sector's middle half▼ 81.4%-€1.6mbelow the sector's middle half€12.6mabove the sector's middle half€16.4mabove the sector's middle half▲ 29.8%
Total assets€59.4m-€66.0m▲ 11.0%€90.1mabove the sector's middle half▲ 36.6%€82.0mabove the sector's middle half▼ 8.9%€53.1mabove the sector's middle half▼ 35.3%€47.2mabove the sector's middle half▼ 11.1%€16.0mabove the sector's middle half▼ 66.2%€18.8mabove the sector's middle half▲ 17.8%
Debt€56.4m-€56.6m▲ 0.4%€52.3m▼ 7.5%€50.7m▼ 3.1%€47.3m▼ 6.8%€48.8m▲ 3.2%€3.3m▼ 93.2%€2.4m▼ 27.8%
Working capital-€48.2m--€41.8m▲ 13.3%€25.2mabove the sector's middle half€25.8mabove the sector's middle half▲ 2.3%-€7.2mbelow the sector's middle half-€14.1mbelow the sector's middle half▼ 97.2%€0.2mwithin the sector's middle half€1.1mwithin the sector's middle half▲ 425%
Solvency5.1%-14.2%▲ 9.1pp41.9%within the sector's middle half▲ 27.7pp38.2%within the sector's middle half▼ 3.7pp11.0%below the sector's middle half▼ 27.2pp-3.3%below the sector's middle half▼ 14.2pp79.1%above the sector's middle half▲ 82.4pp87.2%above the sector's middle half▲ 8.1pp
Current ratio0.14-0.26▲ 0.121.48within the sector's middle half▲ 1.221.51within the sector's middle half▲ 0.030.85below the sector's middle half▼ 0.660.71below the sector's middle half▼ 0.141.06below the sector's middle half▲ 0.351.44within the sector's middle half▲ 0.38
Return on assets (ROA)0.6%-20.2%▲ 19.6pp31.5%above the sector's middle half▲ 11.3pp-7.8%below the sector's middle half▼ 39.3pp-0.9%below the sector's middle half▲ 6.9pp-15.6%below the sector's middle half▼ 14.7pp-5.2%below the sector's middle half▲ 10.5pp-1.2%below the sector's middle half▲ 3.9pp
Staff (FTE)5.4-9.4▲ 74.1%9.6within the sector's middle half▲ 2.1%9.8within the sector's middle half▲ 2.1%9.8within the sector's middle half=19.1within the sector's middle half▲ 94.9%19.8within the sector's middle half▲ 3.7%13.6within the sector's middle half▼ 31.3%
above
within
below
the middle half of NACE 46, Wholesale trade: a quarter of companies sit below it, a quarter above. Each year compared with accounts in the same format, and only where there are at least 30.
Why a figure moved sharply
- 2024 Net result +89% on 2023. Merger absorbing PHARMA-PACK, effective 21-06-2023, in the previous financial year; now counts for a full year for the first time.
- 2023 Turnover +58%, Net result -1,364%, Staff (FTE) +95% on 2022. Merger absorbing PHARMA-PACK, effective 21-06-2023.
- 2022 Net result +92% on 2021. Merger absorbing INFINITY PHARMA, Official Gazette 26-07-2021, in the previous financial year; now counts for a full year for the first time.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €18.8m
Fixed assets
€15.3m ▲ 23.4%
Current assets
€3.5m ▼ 2.1%
Equity and liabilities €18.8m
Equity
€16.4m ▲ 29.8%
Debt
€2.4m ▼ 27.8%
Debt's share of the balance-sheet total falls from 20.9% to 12.8%. Equity is higher and debt is lower.
Key figures and ratios
EBITDA
€19,095▲
2024 · -€413,899
Cash flow
-€139,711▲
2024 · -€705,411
Quick ratio
0.41▲
2024 · 0.27
Debt to equity
0.15▼
2024 · 0.26
ROE
-1.4%▲
2024 · -6.5%
Interest coverage
0.35▲
2024 · -0.25
Debt ≤ 1 year
€2.4m▼
2024 · €3.3m
Income taxes
€3,500▲
2024 · -€1,081
Staff costs
€1.5m▼
2024 · €2.0m
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.
Annual accounts
| Line | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|---|---|
| Operating income70/76A | - | - | - | €10.4m | €7.3m | €11.9m | €11.0m | €11.3m | ▲ 2.5% |
| Turnover70 | €11.1m | €10.6m | €15.7m | €10.2m | €7.2m | €11.4m | €10.7m | €10.7m | ▲ 0.6% |
| Change in stocks of work in progress, finished goods and contracts in progress71 | - | - | - | - | - | - | - | €0.3m | - |
| Own construction capitalised72 | - | - | - | - | - | €0.3m | €0 | €0.02m | - |
| Other operating income74 | - | - | - | €0.2m | €0.09m | €0.2m | €0.3m | €0.3m | ▼ 20.8% |
| Non-recurring operating income76A | - | - | - | €0.004m | - | - | - | - | - |
| Operating charges60/66A | - | - | - | €10.9m | €7.3m | €12.2m | €11.6m | €11.4m | ▼ 1.6% |
| Goods for resale, raw materials and consumables60 | - | - | - | €7.0m | €4.3m | €6.2m | €6.1m | €6.3m | ▲ 3.9% |
| Purchases600/8 | - | - | - | €6.1m | €4.5m | €7.7m | €6.0m | €5.8m | ▼ 2.3% |
| Change in stocks: decrease (increase)609 | - | - | - | €0.9m | -€0.2m | -€1.5m | €0.2m | €0.5m | ▲ 248% |
| Services and other goods61 | - | - | - | €2.5m | €2.1m | €3.4m | €3.0m | €3.5m | ▲ 16.3% |
| Remuneration, social security and pensions62 | - | - | - | €1.4m | €0.9m | €2.4m | €2.0m | €1.5m | ▼ 27.5% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | €0.04m | €0.04m | €0.04m | €0.04m | €0.02m | €0.06m | €0.1m | €0.09m | ▼ 21.7% |
| Write-downs on stocks, contracts in progress and trade receivables: additions (reversals)631/4 | - | - | - | -€0.08m | -€0.03m | €0.1m | €0.1m | -€0.1m | - |
| Provisions for liabilities and charges: additions (uses and reversals)635/8 | - | - | - | -€0.004m | - | - | - | - | - |
| Other operating charges640/8 | - | - | - | €0.009m | €0.1m | €0.03m | €0.02m | €0.1m | ▲ 474% |
| Non-recurring operating charges66A | - | - | - | - | - | - | €0.2m | - | - |
| Operating profit (loss)9901 | €1.8m | €1.8m | €2.2m | -€0.5m | -€0.05m | -€0.3m | -€0.5m | -€0.07m | ▲ 86.3% |
| Financial income75/76B | - | - | - | €0.7m | €0.9m | €1.5m | €1.5m | €0.2m | ▼ 88.7% |
| Recurring financial income75 | €0.2m | €13.4m | €1.8m | €0.7m | €0.9m | €1.5m | €1.5m | €0.2m | ▼ 88.7% |
| Income from current assets751 | - | - | - | €0.7m | €0.9m | €1.5m | €1.5m | €0.001m | ▼ 99.9% |
| Other financial income752/9 | - | - | - | €0.004m | €0.004m | €0.008m | €0.006m | €0.2m | ▲ 27× |
| Non-recurring financial income76B | - | - | - | - | €499 | - | €327 | €17 | ▼ 94.9% |
| Financial charges65/66B | - | - | - | €6.7m | €1.5m | €8.6m | €1.8m | €0.3m | ▼ 81.9% |
| Recurring financial charges65 | €1.6m | €1.5m | €1.4m | €1.2m | €1.5m | €2.9m | €1.8m | €0.3m | ▼ 81.9% |
| Debt charges650 | €1.4m | €1.3m | €1.2m | €1.1m | €1.4m | €2.7m | €1.7m | €0.05m | ▼ 96.8% |
| Other financial charges652/9 | - | - | - | €0.1m | €0.1m | €0.1m | €0.1m | €0.3m | ▲ 151% |
| Non-recurring financial charges66B | - | - | - | €5.5m | - | €5.7m | - | - | - |
| Profit (loss) for the period before taxes9903 | €0.5m | €13.7m | €28.6m | -€6.4m | -€0.7m | -€7.4m | -€0.8m | -€0.2m | ▲ 72.3% |
| Income taxes67/77 | €0.1m | €0.3m | €0.2m | -€0.006m | -€0.2m | €0.004m | -€0.001m | €0.003m | - |
| Taxes670/3 | - | - | - | - | €0.002m | €0.004m | - | €0.003m | - |
| Tax adjustments and reversals of tax provisions77 | - | - | - | €0.006m | €0.2m | - | €0.001m | - | - |
| Profit (loss) for the period9904 | €0.4m | €13.3m | €28.4m | -€6.4m | -€0.5m | -€7.4m | -€0.8m | -€0.2m | ▲ 71.9% |
| Profit (loss) for the period to be appropriated9905 | €0.4m | €13.3m | €28.4m | -€6.4m | -€0.5m | -€7.4m | -€0.8m | -€0.2m | ▲ 71.9% |
| Line | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||
| Total assets20/58 | €59.4m | €66.0m | €90.1m | €82.0m | €53.1m | €47.2m | €16.0m | €18.8m | ▲ 17.8% |
| Fixed assets21/28 | €51.2m | €51.2m | €12.6m | €5.6m | €13.0m | €12.5m | €12.4m | €15.3m | ▲ 23.4% |
| Intangible fixed assets21 | €0.07m | €0.05m | €0.02m | €0.007m | €0.002m | €0.3m | €0.4m | €0.3m | ▼ 22.4% |
| Tangible fixed assets22/27 | €0.07m | €0.06m | €0.04m | €0.04m | €0.03m | €0.3m | €0.04m | €0.04m | ▼ 1.2% |
| Plant, machinery and equipment23 | - | - | - | €0.04m | €0.03m | €0.03m | €0.02m | €0.02m | ▲ 8.0% |
| Furniture and vehicles24 | - | - | - | €418 | €115 | €0.008m | €0.005m | €0.006m | ▲ 13.9% |
| Leasing and similar rights25 | - | - | - | - | - | €0 | - | - | - |
| Other tangible fixed assets26 | - | - | - | - | - | €0 | - | - | - |
| Assets under construction and advance payments27 | - | - | - | - | €0.004m | €0.2m | €0.02m | €0.02m | ▼ 12.3% |
| Financial fixed assets28 | €51.1m | €51.1m | €12.5m | €5.5m | €12.9m | €12.0m | €12.0m | €15.0m | ▲ 25.0% |
| Affiliated companies280/1 | - | - | - | €5.5m | €12.9m | €12.0m | €12.0m | €15.0m | ▲ 25.0% |
| Participating interests280 | - | - | - | €5.5m | €12.9m | €12.0m | €12.0m | €15.0m | ▲ 25.0% |
| Other financial fixed assets284/8 | - | - | - | €0.001m | €0.001m | €0.003m | €0.003m | €0.003m | = |
| Amounts receivable and cash guarantees285/8 | - | - | - | €0.001m | €0.001m | €0.003m | €0.003m | €0.003m | = |
| Current assets29/58 | €8.2m | €14.8m | €77.5m | €76.5m | €40.1m | €34.7m | €3.5m | €3.5m | ▼ 2.1% |
| Stocks and contracts in progress3 | €1.9m | €2.0m | €2.1m | €1.2m | €1.5m | €2.9m | €2.6m | €2.5m | ▼ 5.5% |
| Stocks30/36 | - | - | - | €1.2m | €1.5m | €2.9m | €2.6m | €2.5m | ▼ 5.5% |
| Raw materials and consumables30/31 | - | - | - | - | €0.2m | €1.0m | €0.8m | €0.8m | ▼ 1.4% |
| Work in progress32 | - | - | - | - | €0.01m | €64 | €0 | - | - |
| Finished goods33 | - | - | - | - | €0.03m | €0.2m | €0.3m | €0.5m | ▲ 103% |
| Goods purchased for resale34 | - | - | - | €1.2m | €1.2m | €1.7m | €1.6m | €1.2m | ▼ 25.4% |
| Amounts receivable within one year40/41 | €2.8m | €0.2m | €75.3m | €75.0m | €38.5m | €31.5m | €0.7m | €0.3m | ▼ 65.1% |
| Trade receivables40 | - | - | - | - | €0.3m | €0.4m | €0.6m | €0.3m | ▼ 55.5% |
| Other amounts receivable41 | - | - | - | €75.0m | €38.2m | €31.1m | €0.2m | €0.001m | ▼ 99.5% |
| Current investments50/53 | - | - | €0 | €0 | €0 | €0 | €0 | €0 | = |
| Own shares50 | - | - | - | €0 | €0 | €0 | €0 | €0 | = |
| Cash at bank and in hand54/58 | €3.5m | €12.6m | €0.1m | €0.2m | €0.1m | €0.3m | €0.2m | €0.7m | ▲ 320% |
| Deferred charges and accrued income490/1 | - | - | - | €0.02m | €0.009m | €0.03m | €0.01m | €0.04m | ▲ 139% |
| Equity and liabilities | |||||||||
| Total equity and liabilities10/49 | €59.4m | €66.0m | €90.1m | €82.0m | €53.1m | €47.2m | €16.0m | €18.8m | ▲ 17.8% |
| Equity10/15 | €3.0m | €9.4m | €37.7m | €31.3m | €5.8m | -€1.6m | €12.6m | €16.4m | ▲ 29.8% |
| Contributions10/11 | €1.7m | €1.7m | €1.7m | €1.7m | €1.7m | €1.7m | €9.3m | €13.3m | ▲ 43.0% |
| Capital10 | - | - | - | €1.7m | €1.7m | €1.7m | €9.3m | €13.3m | ▲ 43.0% |
| Issued capital100 | - | - | - | €1.7m | €1.7m | €1.7m | €9.3m | €13.3m | ▲ 43.0% |
| Reserves13 | €1.4m | €7.7m | €36.1m | €29.7m | €4.2m | €4.2m | €4.2m | €3.3m | ▼ 19.8% |
| Non-distributable reserves130/1 | - | - | - | €1.3m | €1.3m | €1.3m | €1.3m | €1.3m | = |
| Legal reserve130 | - | - | - | €1.3m | €1.3m | €1.3m | €1.3m | €1.3m | = |
| Own shares acquired1312 | - | - | - | €0 | €0 | €0 | €0 | €0 | = |
| Tax-exempt reserves132 | - | - | - | €0.02m | €0.02m | €0.02m | €0.02m | €0.02m | = |
| Distributable reserves133 | - | - | - | €28.4m | €2.8m | €2.8m | €2.8m | €2.0m | ▼ 28.9% |
| Profit (loss) carried forward14 | - | - | - | - | - | -€7.4m | -€0.8m | -€0.2m | ▲ 71.9% |
| Amounts payable17/49 | €56.4m | €56.6m | €52.3m | €50.7m | €47.3m | €48.8m | €3.3m | €2.4m | ▼ 27.8% |
| Amounts payable within one year42/48 | €56.4m | €56.6m | €52.3m | €50.7m | €47.3m | €48.8m | €3.3m | €2.4m | ▼ 27.8% |
| Current portion of amounts payable after more than one year42 | - | - | - | - | - | €0 | - | - | - |
| Financial debts43 | - | - | - | €48.5m | €44.9m | €44.9m | €0 | €0 | - |
| Other loans439 | - | - | - | €48.5m | €44.9m | €44.9m | €0 | €0 | - |
| Trade debts44 | €1.8m | €1.7m | €1.8m | €1.7m | €2.0m | €2.5m | €2.4m | €2.2m | ▼ 5.7% |
| Suppliers440/4 | - | - | - | €1.7m | €2.0m | €2.5m | €2.4m | €2.2m | ▼ 5.7% |
| Advances received on contracts in progress46 | - | - | - | €0.005m | €0.005m | €0.005m | €0.005m | €0.005m | = |
| Taxes, remuneration and social security45 | - | - | - | €0.5m | €0.3m | €0.7m | €0.3m | €0.2m | ▼ 43.2% |
| Taxes450/3 | - | - | - | €0.3m | €0.1m | €0.2m | €0.2m | €0.03m | ▼ 78.6% |
| Remuneration and social security454/9 | - | - | - | €0.2m | €0.2m | €0.4m | €0.2m | €0.2m | ▼ 11.4% |
| Other amounts payable47/48 | - | - | - | €0.004m | - | €0.7m | €0.7m | €104 | ▼ 100.0% |
| Accrued charges and deferred income492/3 | - | - | - | €0.001m | - | - | - | - | - |
| Line | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|---|---|
| Profit (loss) for the period9904 | €0.4m | €13.3m | €28.4m | -€6.4m | -€0.5m | -€7.4m | -€0.8m | -€0.2m | ▲ 71.9% |
| + Depreciation and write-downs630 | €0.04m | €0.04m | €0.04m | €0.04m | €0.02m | €0.06m | €0.1m | €0.09m | ▼ 21.7% |
| Operating cash flow (approximation) | €0.4m | €13.4m | €28.4m | -€6.4m | -€0.5m | -€7.3m | -€0.7m | -€0.1m | ▲ 80.2% |
| Investment in fixed assets (approximation) | - | -€0.001m | €38.6m | €7.0m | -€7.4m | €0.4m | -€0.002m | -€3.0m | ▼ 156,581% |
| Change in cash | - | €9.1m | -€12.5m | €0.1m | -€0.1m | €0.1m | -€0.1m | €0.5m | - |
Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.
Latest 10 of 49 filings with the National Bank
| Financial year | Type | Filed | Reference |
|---|---|---|---|
| 31-12-2025 | full format | 11-06-2026 | 2026-00157374 |
| 31-12-2024 | full format | 15-09-2025 | 2025-00493685 |
| 31-12-2023 | full format | 07-06-2024 | 2024-00119284 |
| 31-12-2022 | full format | 05-06-2023 | 2023-00109744 |
| 31-12-2021 | full format | 31-05-2022 | 2022-20042942 |
| 31-12-2020 | full format | 25-05-2021 | 2021-15200233 |
| 31-12-2019 | full format | 31-05-2020 | 2020-13900411 |
| 31-12-2018 | full format | 23-05-2019 | 2019-14100048 |
| 31-12-2017 | full format | 23-05-2018 | 2018-13500082 |
| 31-12-2016 | full format | 09-05-2017 | 2017-11500389 |
Similar companies · same sector, comparable size
MEDISCH LABO SERVICE
BE 0429.447.902
Menen · equity €16.7m
sandoz
BE 0457.517.227
Machelen (Brab.) · equity €16.8m
VOLCANO EUROPE
BE 0859.842.345
Zaventem · equity €17.0m
THERABEL IMMO
BE 0428.944.292
Vorst · equity €15.6m
BIOGEN BELGIUM
BE 0462.285.469
Machelen (Brab.) · equity €15.4m
Of the 1,869 active companies whose main activity is wholesale of pharmaceutical and medical goods (NACE 46460), figures are known for 1,120. 360 are within a factor 10 of this equity. These 5 are the closest to it. See the whole sector
Public contracts: No European public contracts awarded found since October 2016. Contracts below the EU thresholds are not in TED.